Ketoanalogue-Supplemented Very Low-Protein Diet May Benefit CKD

This article originally appeared here.
Share this content:
Ketoanalogue-Supplemented Very Low-Protein Diet May Benefit CKD
Ketoanalogue-Supplemented Very Low-Protein Diet May Benefit CKD

FRIDAY, Jan. 29, 2016 (HealthDay News) -- A ketoanalogue-supplemented vegetarian very low-protein diet (KD) seems safe and may be able to slow chronic kidney disease progression, according to a study published online Jan. 28 in the Journal of the American Society of Nephrology.

Liliana Garneata, M.D., Ph.D., from the "Carol Davila" University of Medicine and Pharmacy in Bucharest, Romania, and colleagues conducted a prospective, randomized controlled trial of the safety and efficacy of KD versus conventional low-protein diet (LPD). Adults without diabetes and with stable estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m², proteinuria <1 g/g urinary creatinine, good nutritional status, and good diet compliance entered a run-in LPD phase. Compliant patients were randomized after three months to KD or to continue LPD for 15 months.

The researchers found that to avoid the primary end point of renal replacement therapy initiation or >50 percent reduction in initial eGFR, the adjusted numbers needed to treat (NNT) were 4.4 and 4.0 in intention-to-treat and per-protocol analyses, respectively, for patients with eGFR <30 ml/min/m². To avoid dialysis, the adjusted NNT was 22.4 for patients with eGFR <30 ml/min/1.73 m² and decreased to 2.7 for patients with eGFR of <20 ml/min/1.73 m². With KD only there was correction of metabolic abnormalities. Diet compliance was good and there were no changes in nutritional parameters or adverse reactions.

"This KD seems nutritionally safe and could defer dialysis initiation in some patients with CKD," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »